These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 32639983)

  • 1. Patient preferences for reducing bowel adverse events following prostate radiotherapy.
    Mishra MV; Thayer WM; Janssen E; Hoppe B; Eggleston C; Bridges JFP
    PLoS One; 2020; 15(7):e0235616. PubMed ID: 32639983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding.
    Lee JY; Daignault-Newton S; Heath G; Scarlett S; Sanda MG; Chang P; Regan MM; Michalski JM; Sandler HM; Feng FY; Kuban DA; Zietman AL; Ciezki JP; Kaplan ID; Crociani C; McLaughlin WP; Mantz CA; Finkelstein SE; Suy S; Collins SP; Garin O; Ferrer M; Hamstra DA; Spratt DE
    Int J Radiat Oncol Biol Phys; 2016 Nov; 96(4):770-777. PubMed ID: 27663760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross validation of the prostate cancer radiotherapy late toxicity (PCRT) questionnaire with the expanded prostate cancer index composite (EPIC) instrument.
    Rodrigues G; Bauman G; Venkatesan V; Ahmad B; Lock M; Sexton T; D'Souza D; Stitt L; Eid S
    Can J Urol; 2011 Aug; 18(4):5802-10. PubMed ID: 21854712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience.
    Hamstra DA; Conlon AS; Daignault S; Dunn RL; Sandler HM; Hembroff AL; Zietman AL; Kaplan I; Ciezki J; Kuban DA; Wei JT; Sanda MG; Michalski JM;
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):546-53. PubMed ID: 23561651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of pelvic radiotherapy for prostate cancer on bowel, bladder, and sexual function: the patient's perspective.
    Crook J; Esche B; Futter N
    Urology; 1996 Mar; 47(3):387-94. PubMed ID: 8633407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanded validation of the EPIC bowel and urinary domains for use in women with gynecologic cancer undergoing postoperative radiotherapy.
    Gil KM; Pugh SL; Klopp AH; Yeung AR; Wenzel L; Westin SN; Gaffney DK; Small W; Thompson S; Doncals DE; Cantuaria GHC; Yaremko BP; Chang A; Kundapur V; Mohan DS; Haas ML; Kim YB; Ferguson CL; Deshmukh S; Kachnic LA; Bruner DW
    Gynecol Oncol; 2019 Jul; 154(1):183-188. PubMed ID: 31104905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population.
    Hanlon AL; Watkins Bruner D; Peter R; Hanks GE
    Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):51-9. PubMed ID: 11163497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating preferences for treatments in patients with localized prostate cancer.
    Ávila M; Becerra V; Guedea F; Suárez JF; Fernandez P; Macías V; Mariño A; Hervás A; Herruzo I; Ortiz MJ; Ponce de León J; Sancho G; Cunillera O; Pardo Y; Cots F; Ferrer M;
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):277-87. PubMed ID: 25491504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Piloting prostate cancer patient-reported outcomesin clinical practice.
    Korzeniowski M; Kalyvas M; Mahmud A; Shenfield C; Tong C; Zaza K; Howell D; Brundage M
    Support Care Cancer; 2016 May; 24(5):1983-1990. PubMed ID: 26498748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score.
    Simone NL; Ménard C; Soule BP; Albert PS; Guion P; Smith S; Godette D; Crouse NS; Sciuto LC; Cooley-Zgela T; Camphausen K; Coleman CN; Singh AK
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):90-5. PubMed ID: 17855015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life after whole pelvic versus prostate-only external beam radiotherapy for prostate cancer: a matched-pair comparison.
    Pinkawa M; Piroth MD; Holy R; Fischedick K; Klotz J; Székely-Orbán D; Eble MJ
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):23-8. PubMed ID: 20832182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of acute bowel function after radiotherapy for prostate cancer: Is it accurate enough?
    Bonet M; Cayetano L; Núñez M; Jovell-Fernández E; Aguilar A; Ribas Y
    Clin Transl Oncol; 2018 May; 20(5):576-583. PubMed ID: 28900813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is "pelvic radiation disease" always the cause of bowel symptoms following prostate cancer intensity-modulated radiotherapy?
    Min M; Chua B; Guttner Y; Abraham N; Aherne NJ; Hoffmann M; McKay MJ; Shakespeare TP
    Radiother Oncol; 2014 Feb; 110(2):278-83. PubMed ID: 24412017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life in T1-3N0 prostate cancer patients treated with radiation therapy with minimum 10-year follow-up.
    Johnstone PA; Gray C; Powell CR
    Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):833-8. PubMed ID: 10705003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial results of a randomized phase III trial of high dose image guided radiation with or without androgen deprivation therapy for intermediate-risk prostate cancer.
    Vargas CE; Alam NB; Terk M; Niska JR; Cesaretti J; Swartz D; Vashi A; Kasraeian A; West CS; Blasser M; Moore C
    Cancer Treat Res Commun; 2019; 19():100119. PubMed ID: 30772671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.
    Lane A; Metcalfe C; Young GJ; Peters TJ; Blazeby J; Avery KN; Dedman D; Down L; Mason MD; Neal DE; Hamdy FC; Donovan JL;
    BJU Int; 2016 Dec; 118(6):869-879. PubMed ID: 27415448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Living alone, obesity and smoking: important factors for quality of life after radiotherapy and androgen deprivation therapy for prostate cancer.
    Dieperink KB; Hansen S; Wagner L; Johansen C; Andersen KK; Hansen O
    Acta Oncol; 2012 Jul; 51(6):722-9. PubMed ID: 22793038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose to the inferior rectum is strongly associated with patient reported bowel quality of life after radiation therapy for prostate cancer.
    Stenmark MH; Conlon AS; Johnson S; Daignault S; Litzenberg D; Marsh R; Ritter T; Vance S; Kazzi N; Feng FY; Sandler H; Sanda MG; Hamstra DA
    Radiother Oncol; 2014 Feb; 110(2):291-7. PubMed ID: 24507766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensity-modulated radiotherapy of prostate cancer with simultaneous integrated boost after molecular imaging with 18F-choline-PET/CT : Clinical results and quality of life.
    Schlenter M; Berneking V; Krenkel B; Mottaghy FM; Vögeli TA; Eble MJ; Pinkawa M
    Strahlenther Onkol; 2018 Jul; 194(7):638-645. PubMed ID: 29511777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study.
    Hamilton AS; Stanford JL; Gilliland FD; Albertsen PC; Stephenson RA; Hoffman RM; Eley JW; Harlan LC; Potosky AL
    J Clin Oncol; 2001 May; 19(9):2517-26. PubMed ID: 11331331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.